Why the acne on your jaw is different from teen acne
You're 28, or 34, or 40. Your acne is nothing like what you had at 15. It's deep, cystic, concentrated along your jaw and chin, and it tracks your cycle almost reliably. You've been prescribed topicals that work on surface oil. Those help with a different kind of acne.
Adult hormonal acne is driven from the inside. Androgens — testosterone and its derivatives — stimulate oil glands to overproduce sebum. Blocked pores, bacteria, inflammation: that's the downstream cascade. Treating it at the skin surface is like mopping up a leak without fixing the pipe. Spironolactone works at the source: it blocks androgen receptors in the skin, so the oil glands don't get the signal to go into overdrive.
What the evidence actually shows
Spironolactone was originally developed as a blood pressure medication. Its anti-androgen effects were discovered incidentally, and dermatologists have been using it off-label for hormonal acne for decades. The evidence base has grown substantially.
The 2025 systematic review in JAAD Reviews searched literature through February 2025 and identified 68 studies — 16 of which were randomized controlled trials. The conclusion was unambiguous: spironolactone is effective for moderate-to-severe acne in adult women, with a strong safety profile at standard doses.
A 2025 Australian meta-analysis in the Australasian Journal of Dermatology found that spironolactone reduced acne severity significantly compared to placebo, with no meaningful increase in adverse events including menstrual irregularities and breast tenderness. The safety finding is clinically important: a common reason doctors hesitate to prescribe it is fear of side effects that the evidence doesn't strongly support at standard doses.
Who is — and isn't — a candidate
Spironolactone is for adult women with hormonally driven acne. The profile: acne concentrated on the lower face and jaw, worsening in the week before a period, persistent despite topical treatments, and typically starting or worsening in the mid-to-late 20s or 30s.
It's not appropriate for women who are pregnant or actively trying to conceive. Spironolactone is teratogenic — it can cause feminisation of a male fetus — so effective contraception is required for anyone taking it who could become pregnant. It's also a diuretic, which means potassium monitoring is standard, particularly at higher doses or in women with kidney concerns. These aren't reasons to avoid it — they're reasons it requires a prescriber, not a supplement aisle.
If you have textbook hormonal acne and you've never been offered spironolactone, that's a gap in care — not an unusual one, but a gap. Most GPs don't think to offer it; most dermatologists are more familiar with it. Knowing the name and the evidence gives you the language to ask for it directly.
What to tell your doctor
- Describe the pattern specifically: location (jaw, chin, lower cheeks), timing relative to your cycle, depth and severity, and how long it's been happening
- Ask directly: "I've read about spironolactone for hormonal acne — is that something that might be appropriate for me?"
- If you're seeing a GP, ask for a dermatology referral — dermatologists are more likely to prescribe and monitor this medication confidently
- Clarify your contraception status upfront — it's a required conversation and will move the assessment forward faster
Spironolactone is a prescription medication requiring individual assessment. It is contraindicated in pregnancy and requires appropriate contraception. Potassium levels are typically monitored during treatment. Discuss your full medical history, including any kidney conditions or medications, before starting this treatment.
- Yung A et al. (2025). Oral spironolactone for acne vulgaris in females: evidence review and practical recommendations. JAAD Reviews. S2950-1989(25)00064-9.
- Kow ASF et al. (2025). Spironolactone for the treatment of moderate to severe acne in adult women: a systematic review and meta-analysis. Australasian Journal of Dermatology. doi:10.1111/ajd.14428.
- PMC (2025). Efficacy and safety of oral spironolactone for women with acne vulgaris: a systematic review and meta-analysis. PMC12359290.
- Dermatology Advisor (2025). Oral spironolactone may improve acne vulgaris in women.